Chronic Bronchitis and Emphysema Treatment
Chronic Bronchitis and Emphysema Treatment
Treatment here is organised around a distinction that is easy to miss: some things relieve symptoms, some reduce the risk of an exacerbation, and one thing changes how fast the disease progresses. Getting those three apart prevents both wasted effort and unnecessary disappointment. This page sets out what each part of treatment does and does not do, and why the device, the exercise and the plan are treatment rather than advice.
Two arms of treatment, and what each one can and cannot do
The first arm opens the airways. Bronchodilators relax the muscle wrapped around them, which reduces breathlessness, allows more activity and reduces the frequency of exacerbations to some degree. The second arm reduces inflammation, and consists chiefly of an inhaled corticosteroid, added for people whose pattern of inflammation makes it likely to help. Both are medicines, and neither of them changes the underlying course.
| Treatment | What it does | What it does not do |
|---|---|---|
| Bronchodilators, short and long acting | Open the airways, relieve breathlessness, increase what a person can do, and reduce exacerbations to some degree | They do not change the rate at which lung function falls, and they do not remove the diagnosis |
| Inhaled corticosteroid, in selected people | Reduces exacerbations in those whose inflammation pattern predicts a response | It is not for everyone, and in people who do not fit that pattern the risk of pneumonia may outweigh the gain |
| Stopping smoking | Slows the rate at which lung function continues to fall, and reduces exacerbations | It does not restore lung function already lost, and it does not reverse emphysema |
| Pulmonary rehabilitation | Improves exercise capacity, breathlessness and quality of life, and reduces admissions after an exacerbation | It does not change the spirometry figures; what it changes is what those figures allow |
| Long-term oxygen, in selected people | Improves survival and other outcomes in those whose blood oxygen persistently meets defined thresholds | It does not relieve breathlessness in people who are not hypoxaemic, and it is not a general tonic |
| Vaccination and an action plan | Reduce the infections that trigger exacerbations, and shorten the delay before an exacerbation is treated | They do not replace any of the treatments above |
A practical distinction sits inside the first row. A reliever is used when breathlessness occurs and works within minutes; a maintenance bronchodilator is taken regularly whether or not there are symptoms, because its effect is to keep the airways open rather than to reopen them after they have narrowed. Reaching for a reliever more often than before is a signal to review the maintenance treatment, not to buy more reliever.
Much of what determines how the disease behaves happens between prescriptions. Smoking status, vaccination, physical activity, weight, sleep and mood are addressed alongside the inhalers, and each of them is discussed on this page or on the living-with-it page.
Inhalers — what the classes do, and why the device matters
Inhaled treatment falls into a small number of groups. Short-acting bronchodilators relieve symptoms within minutes and are used as needed. Long-acting bronchodilators are taken regularly; there are two families, and they can be combined in one device. Where an inhaled corticosteroid is added, it is usually combined with a long-acting bronchodilator rather than given alone. Which combination applies is decided from the numbers described on the diagnosis page, not from preference.
The device is part of the treatment, and this is not a slogan: a medicine that does not reach the airways has not been given. A correctly chosen prescription delivered through a device used incorrectly produces the result of no treatment at all, while looking entirely satisfactory on the prescription chart.
The errors are consistent enough to be predictable. Not shaking a pressurised inhaler before use, or not priming a new one. Pressing and breathing in at the wrong moment, so that the dose lands on the tongue. Breathing in too fast through a device that needs a slow, steady breath, or too slowly through a dry powder device that needs a quick deep one. Not holding the breath afterwards. Not rinsing the mouth when a corticosteroid is involved. And carrying on with a device that has run out, because some of them do not rattle.
What corrects it is observation rather than further explanation: the technique watched, on the actual device, by somebody who knows that device, and repeated at every review. A spacer with a pressurised inhaler improves delivery and reduces how much of the dose stays in the mouth. And a device should be chosen to suit the person using it — hand strength, coordination and breathing pattern all matter — because a device that cannot be used properly is not a treatment.
One caution about switching. Moving someone from one device to another without teaching the new one reliably turns a stable situation into an unstable one. If the device changes, the technique should be taught and checked on the new device before the old one is given up.
Stopping smoking — the intervention that changes the course
This is the single most important paragraph on the site for anyone still smoking. Everything else in treatment relieves symptoms, improves capacity or reduces the risk of an exacerbation. Stopping smoking does those things as well, and it is the intervention that slows the rate at which lung function continues to fall.
What needs saying accurately is what it does not do, because overstating the case is how people end up disappointed and smoking again. Stopping does not repair destroyed alveoli, does not restore lung function already lost and does not remove the diagnosis. What it does is change the slope: the decline continues, but more slowly, closer to the rate seen in people who have never smoked. Continuing to smoke, in addition, reduces the benefit obtainable from inhaled treatment and increases the frequency of exacerbations.
The methods that work are unglamorous. Behavioural support plus medication is more effective than either alone, and medication options include nicotine replacement in its various forms and prescription medicines that reduce craving; which applies is a clinical decision. Setting a quit date, removing cigarettes and ashtrays from the house and the car, and identifying the situations that trigger smoking in advance all improve the odds.
Relapse is part of the process rather than the end of it. Most people who stop for good have made several attempts, and each attempt is not a failure but information about what to change next time. That is worth knowing before the first attempt rather than afterwards.
Two related points. Second-hand smoke matters, particularly for anyone in the household with the same disease or with children. And electronic cigarettes deserve a careful sentence rather than an advertisement: they are not established as harmless, they are not a first-line treatment in clinical guidance, and using them while continuing to smoke conventional cigarettes is not a path to stopping. The goal is not a substitute; it is stopping.
For someone who has smoked for forty years, the honest position is that stopping is worth doing at any age and at any stage of the disease, and it is the one thing on this page that changes how the disease behaves rather than how it feels.
Pulmonary rehabilitation — the most underused part of treatment
Pulmonary rehabilitation is a supervised programme rather than a piece of advice, and it is the part of treatment most often omitted. It combines exercise training with breathing techniques, positions and pacing for breathlessness, airway clearance where sputum is troublesome, nutritional advice, and education about the disease and its medicines.
What it changes is not the lungs. The spirometry figures before and after a programme are essentially the same, which is exactly why its value is easy to dismiss and easy to explain: it improves what a person can do with the lung function they have. Exercise capacity increases, breathlessness for a given task falls, and quality of life improves. After an exacerbation, a programme reduces the chance of being readmitted.
That is the answer to a question patients ask in different words: if the numbers cannot be improved, what is the point of doing anything? The point is that the numbers describe a capability rather than a life. Two people with the same figures can differ by kilometres of walking, and rehabilitation is the part of treatment that moves a person from one end of that range to the other.
It suits anyone who remains limited by breathlessness despite well-delivered inhaled treatment, and particularly anyone recovering from an exacerbation, since that is when capacity falls most sharply. What a programme contains is standard, but how much is available locally varies, and it is worth asking at every review what is on offer, and whether anything is available closer to home.
It is also worth knowing that the assessment it depends on — lung function, exercise measurement and oxygen saturation — is the same assessment described on the diagnosis page, so the programme starts from numbers rather than from an impression.
Exacerbations — treatment, and the review that prevents the next
At home, treatment of an exacerbation follows the written plan. The bronchodilator is increased, most often through a spacer where a pressurised inhaler is used. A short course of an oral corticosteroid is started where the plan and the prescriber allow it. An antibiotic is considered when the sputum has become purulent or infection is otherwise judged likely, and whether it is appropriate is a clinical decision rather than a colour-matching exercise. Escalation to assessment happens when the plan says so, rather than when the person runs out of other ideas.
In hospital, treatment follows a standard sequence: oxygen given to a target range rather than freely, because uncontrolled oxygen can raise the carbon dioxide in people whose breathing drive depends partly on a low oxygen level; repeated bronchodilator; an early systemic corticosteroid; antibiotics where indicated; and assisted ventilation for the most severe episodes. Non-invasive ventilation — support delivered through a tight-fitting mask rather than a tube — is used for episodes with carbon dioxide retention and reduces the need for intubation in that group.
Our respiratory and critical care medicine department manages the acute phase in-house, including mechanical ventilation when the breathing needs support. Whether an episode is treated and the person goes home, is observed, or is admitted follows the response to the first treatments rather than how unwell the person looked on arrival.
The part most often missed is what happens afterwards. An exacerbation is evidence that something failed, and the review that follows is where the next one is prevented: was the inhaler technique still right, was the maintenance treatment being taken, had something changed in the environment or at work, was the vaccination status up to date, was the plan findable and understood, and does the oxygen assessment need repeating. A recovery programme of exercise or rehabilitation is considered at this point, because capacity falls fastest during an episode and is hardest to regain without help.
What a plan should contain, and what should be written down before discharge, is set out on the living-with-it page.
Oxygen — a treatment with indications, not a tonic
Oxygen is simultaneously over-requested and feared, and both attitudes come from the same misunderstanding. It is a medicine with defined indications, not a substance that is good for lungs in general and not something that harms everyone who touches it. Whether it helps depends entirely on whether the blood oxygen level meets the criteria.
Long-term oxygen therapy is prescribed for people whose oxygen pressure or saturation is persistently low enough to meet defined thresholds — assessed when stable, not during an exacerbation — and for a smaller intermediate group whose level is borderline but who have evidence of the effects of chronic low oxygen, such as right-heart strain or a raised red-cell count. Where it is prescribed, it is used for most of the day, usually including the hours of sleep, because the benefit depends on the number of hours it is used rather than on the flow rate at any given moment.
For anyone who does not meet those criteria, oxygen does not relieve breathlessness and does not improve outcomes, and this is the most useful thing on the page to understand. Breathlessness in COPD comes from trapped air and from deconditioning rather than from a shortage of oxygen in the blood, which is why a person can be very breathless with a normal saturation and why oxygen often does nothing for that sensation. What does help is bronchodilator treatment, pacing and breathlessness-reduction techniques, exercise training, and moving air across the face with a fan or an open window.
There are practical cautions. Oxygen is a drug and supports combustion, so it must be kept away from smoking and from open flames. The flow rate should not be adjusted outside the prescription, because in someone whose carbon dioxide tends to rise, more is not better. Equipment needs to be maintained and replaced as directed, and the prescription needs a review date rather than indefinite renewal.
If the question of oxygen has never been settled, the way to settle it is a measurement made when stable, with the result recorded. That is a short answer to a long-standing uncertainty, and it is better than deciding either way on the basis of how it feels.
When the disease is advanced — the options beyond inhalers
For people with severe disease, treatment does not stop at inhalers, and it also does not consist of escalating inhalers indefinitely. The options that follow are chosen from measurements and from what the person wants, and each of them has a defined place rather than a general one.
Non-invasive ventilation, delivered through a mask, is used for selected people with chronic carbon dioxide retention. In that group it improves survival and reduces hospital admissions, and it is a treatment for the daytime blood gas picture rather than for a single bad night. Where the problem is a specific area of destroyed, over-inflated lung, lung volume reduction — surgical or performed through a bronchoscope — is considered in selected people, and in a smaller group a large bulla can be removed. Lung transplantation is an option for a very small number of people who meet defined criteria, and it is assessed in a specialist setting.
For the inherited form of emphysema, augmentation therapy exists in some countries for people with a confirmed deficiency and the right clinical picture. Availability varies, and the decision is made in a specialist centre; the point worth taking away is that identifying the deficiency is what makes the option visible.
There is also the part of advanced care that is least often written down and most often needed. Symptoms can be relieved even when lung function cannot be improved, including breathlessness, cough, anxiety, poor sleep and pain, and treating those is not a withdrawal of care. Planning ahead — what treatments would be wanted, who makes decisions if a person cannot, and where care should happen — is part of the management of a long-term condition rather than a separate conversation. Discussing it early makes it a plan rather than a crisis.
Which of these applies, and when to consider them, is decided from the numbers, the exacerbation history, the person's own priorities and the assessment of the treating team — and it is a decision to revisit as the disease changes rather than to settle once. What has to be in place whichever options are used is on the living-with-it page.